Trial Profile

A Phase 1/2, Open-label, Multi-center Study to Assess the Safety and Tolerability of Durvalumab (Anti-PDL1 Antibody) as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocitic Leukemia

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 20 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary) ; Bendamustine; Ibrutinib; Lenalidomide; Rituximab
Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Hodgkin's disease; Lymphoma; Mantle-cell lymphoma
Focus Adverse reactions; Therapeutic Use
Acronyms FUSION NHL 001
Sponsors Celgene Corporation

16 Dec 2022 Status changed from active, no longer recruiting to completed.
18 Sep 2022 This trial has been completed in Netherlands, according to European Clinical Trials Database record (21 Aug 2022).
25 Jan 2022 Planned End Date changed from 8 Jul 2022 to 21 Aug 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com